TCA
ABBV icon

Trifecta Capital Advisors’s AbbVie ABBV Stock Holding History

Trifecta Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
41,305
+603
+1% +$130K 1.34% 23
2026
Q1 		$8.85M Buy
40,702
+160
+0.4% +$35.5K 1.37% 21
2025
Q4 		$9.26M Buy
40,542
+614
+2% +$140K 1.37% 23
2025
Q3 		$9.24M Buy
39,928
+900
+2% +$183K 1.41% 22
2025
Q2 		$7.24M Buy
39,028
+1,664
+4% +$309K 1.21% 29
2025
Q1 		$7.83M Buy
37,364
+907
+2% +$176K 1.64% 17
2024
Q4 		$6.48M Buy
36,457
+6,474
+22% +$1.19M 1.28% 24
2024
Q3 		$5.92M Buy
29,983
+148
+0.5% +$27.6K 1.24% 26
2024
Q2 		$5.12M Buy
29,835
+1,070
+4% +$177K 1.13% 27
2024
Q1 		$5.24M Buy
28,765
+26,480
+1,159% +$4.56M 1.28% 22
2023
Q4 		$354K Sell
2,285
-230
-9% -$33.5K 0.1% 71
2023
Q3 		$375K Sell
2,515
-29
-1% -$4.26K 0.12% 69
2023
Q2 		$343K Hold
2,544
– – 0.11% 70
2023
Q1 		$405K Buy
2,544
+29
+1% +$4.43K 0.14% 72
2022
Q4 		$406K Buy
+2,515
New +$386K 0.16% 71

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Trifecta Capital Advisors's ABBV Position: Q2 2026 in Review

Trifecta Capital Advisors increased its AbbVie (ABBV) stake by 1.5% in Q2 2026, buying an estimated $130K and bringing the position to 41,305 shares worth $10.4M. The position accounts for 1.34% of the portfolio, ranked #23.

Trifecta Capital Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Trifecta Capital Advisors held 41,305 shares of AbbVie worth $10.4M as of Q2 2026.
  • Trifecta Capital Advisors bought 603 AbbVie shares in Q2 2026, an estimated $130K.
  • AbbVie made up 1.34% of Trifecta Capital Advisors's portfolio in Q2 2026, its #23 holding.
  • Trifecta Capital Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.